Mounjaro Sales Rise 229% Despite Cheaper Generic Weight-Loss Alternatives
Eli Lilly's Mounjaro, an injectable drug for Type 2 diabetes and weight management, saw a 229% sales increase to Rs 1,544 crore in the year ending October 2026, becoming India's top-selling medicine brand. This growth occurred despite the entry of cheaper generic semaglutide alternatives after patent expiry. Experts suggest Mounjaro's dual hormone receptor action, targeting GIP and GLP-1, may offer greater weight loss and fewer side effects compared to semaglutide, which acts on GLP-1 alone, driving its strong sales.
First-hand measurement across 2 sources
We measured how 2 outlets covered this story. No outlet gave this story a measurable political slant — there is no left–right reading to report. Overall sentiment is neutral (55/100). Lens Score 48/100.
Outlets measured: thefinancialexpress, indianexpress. See how each one headlined and framed the same story in the source comparison below.
AI Analysis
Sentiment was consistent across outlets (55–55/100), indicating broadly factual reporting rather than editorialising.
Coverage timeline
indianexpress broke this story on 10 Nov, 11:16 am. Other outlets followed.